| NCT ID | NCT07635823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Pins Medical Co., Ltd |
| Condition | Parkinson Disease(PD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-05-16 |
| Primary Completion | 2027-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-05-16 with a primary completion date of 2027-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the efficacy and safety of an adaptive deep brain stimulation (aDBS) system for managing Parkinson's disease symptoms. Researchers will compare closed-loop stimulation (which automatically adjusts therapy using real-time brain signals and sleep monitoring) against traditional continuous stimulation (fixed settings) in a randomized, double-blind, crossover study. Participants will undergo surgical implantation of PINS Medical's G1010R neurostimulator, followed by alternating treatment phases where each patient experiences both aDBS and conventional open-loop stimulation modes. Outcomes will assess improvements in without troublesome dyskinesia daily time, motor symptoms (e.g., tremors, rigidity), quality of life, and sleep quality across both therapy periods.
Eligibility Criteria
Inclusion Criteria: * idiopathic Parkinson's disease * Hoehn \& Yahr (HY) stage 2.5-4 during medication "OFF" * Subjects must meet one of the following: 1. Never underwent DBS surgery and suitable for bilateral STN or GPi DBS surgery; 2. Previous bilateral STN/GPi DBS recipients with only one IPG who: * Demonstrate responsiveness to conventional cDBS therapy per investigator evaluation, * Consent to device replacement with G1010R DBS system. * Willing and physically/mentally able to complete all study visits and procedures * Capable of comprehending and providing written informed consent Exclusion Criteria: * Presence of contraindications to deep brain stimulation (DBS) surgery. * Beck Depression Inventory-II (BDI-II) score \> 25 * Mini-Mental State Examination (MMSE) score \< 24 (adjusted for educational level) * Significant comorbidities that may interfere with DBS therapy per investigator assessment. * Pre-existing active non-DBS medical implants or metallic cranial implants * Requirement for diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) during the study period * History of ablative neurosurgery or stem cell therapy for Parkinson's disease * Inability to complete ≥3 consecutive days of comprehensive motor/sleep diaries * Inability to maintain prescribed medication regimens or comply with protocol requirements * Current pregnancy, lactation, or planned pregnancy during the study period * Other conditions deemed by investigators to compromise study suitability * Participation in other interventional clinical trials within 4 weeks prior to consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07635823 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Parkinson Disease(PD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07635823 currently recruiting?
Yes, NCT07635823 is actively recruiting participants. Contact the research team at sunjianguang@pinsmedical.com for enrollment information.
Where is the NCT07635823 trial being conducted?
This trial is being conducted at Hefei, China, Beijing, China, Beijing, China, Beijing, China and 5 additional locations.
Who is sponsoring the NCT07635823 clinical trial?
NCT07635823 is sponsored by Beijing Pins Medical Co., Ltd. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.